GSK Pharma Expands into Oncology and Focuses on Adult Vaccines in India
GlaxoSmithKline (GSK) Pharma is making significant strides in the Indian healthcare market, focusing on two key areas: oncology and adult vaccines. With India's growing population and rising life expectancy, GSK is positioning itself as a leader in preventive healthcare while expanding its specialty portfolio into oncology.
Focus on Adult Vaccines
GSK has been working to build a robust ecosystem for adult immunization in India, recognizing the increasing importance of preventive healthcare. One of its major recent launches was Shingrix, a vaccine for shingles, which has been well-received by healthcare practitioners. GSK is also preparing to introduce new vaccines, such as the Arexvy vaccine for respiratory syncytial virus (RSV), with clinical trials set to start soon. This push reflects a shift from the traditional focus on childhood immunization to a more comprehensive approach for all age groups.
Oncology Expansion
In a significant move, GSK is also entering the oncology market in India. It has introduced two key therapies: Zejula (niraparib), for the maintenance treatment of ovarian cancer, and Jemperli (dostarlimab), a treatment for endometrial cancer. The company sees oncology as a high-growth area and is moving rapidly to commercialize these treatments in the Indian market.
This dual focus on vaccines and oncology is part of GSK’s broader strategy to align with India’s evolving healthcare needs, particularly in light of government initiatives promoting preventive healthcare and improving the quality of care
These expansions underline GSK's commitment to innovation and its evolving role in India's healthcare ecosystem.
source: economictimes.indiatimes
#oncology #dseide
GlaxoSmithKline (GSK) Pharma is making significant strides in the Indian healthcare market, focusing on two key areas: oncology and adult vaccines. With India's growing population and rising life expectancy, GSK is positioning itself as a leader in preventive healthcare while expanding its specialty portfolio into oncology.
Focus on Adult Vaccines
GSK has been working to build a robust ecosystem for adult immunization in India, recognizing the increasing importance of preventive healthcare. One of its major recent launches was Shingrix, a vaccine for shingles, which has been well-received by healthcare practitioners. GSK is also preparing to introduce new vaccines, such as the Arexvy vaccine for respiratory syncytial virus (RSV), with clinical trials set to start soon. This push reflects a shift from the traditional focus on childhood immunization to a more comprehensive approach for all age groups.
Oncology Expansion
In a significant move, GSK is also entering the oncology market in India. It has introduced two key therapies: Zejula (niraparib), for the maintenance treatment of ovarian cancer, and Jemperli (dostarlimab), a treatment for endometrial cancer. The company sees oncology as a high-growth area and is moving rapidly to commercialize these treatments in the Indian market.
This dual focus on vaccines and oncology is part of GSK’s broader strategy to align with India’s evolving healthcare needs, particularly in light of government initiatives promoting preventive healthcare and improving the quality of care
These expansions underline GSK's commitment to innovation and its evolving role in India's healthcare ecosystem.
source: economictimes.indiatimes
#oncology #dseide
GSK Pharma Expands into Oncology and Focuses on Adult Vaccines in India
GlaxoSmithKline (GSK) Pharma is making significant strides in the Indian healthcare market, focusing on two key areas: oncology and adult vaccines. With India's growing population and rising life expectancy, GSK is positioning itself as a leader in preventive healthcare while expanding its specialty portfolio into oncology.
Focus on Adult Vaccines
GSK has been working to build a robust ecosystem for adult immunization in India, recognizing the increasing importance of preventive healthcare. One of its major recent launches was Shingrix, a vaccine for shingles, which has been well-received by healthcare practitioners. GSK is also preparing to introduce new vaccines, such as the Arexvy vaccine for respiratory syncytial virus (RSV), with clinical trials set to start soon. This push reflects a shift from the traditional focus on childhood immunization to a more comprehensive approach for all age groups.
Oncology Expansion
In a significant move, GSK is also entering the oncology market in India. It has introduced two key therapies: Zejula (niraparib), for the maintenance treatment of ovarian cancer, and Jemperli (dostarlimab), a treatment for endometrial cancer. The company sees oncology as a high-growth area and is moving rapidly to commercialize these treatments in the Indian market.
This dual focus on vaccines and oncology is part of GSK’s broader strategy to align with India’s evolving healthcare needs, particularly in light of government initiatives promoting preventive healthcare and improving the quality of care
These expansions underline GSK's commitment to innovation and its evolving role in India's healthcare ecosystem.
source: economictimes.indiatimes
#oncology #dseide
